Candel Therapeutics Files 8-K for Regulatory and Financial Updates
Ticker: CADL · Form: 8-K · Filed: Mar 6, 2024 · CIK: 1841387
Sentiment: neutral
Topics: regulatory-filing, financial-reporting
Related Tickers: CADL
TL;DR
CADL filed an 8-K, standard procedure, no major news.
AI Summary
Candel Therapeutics, Inc. filed an 8-K on March 5, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specific financial figures or material events beyond the reporting of these items.
Why It Matters
This filing indicates Candel Therapeutics is adhering to its reporting obligations with the SEC, which is standard practice for publicly traded companies.
Risk Assessment
Risk Level: low — The filing is a routine 8-K for regulatory and financial disclosures, not indicating any specific new risks or material events.
Key Players & Entities
- Candel Therapeutics, Inc. (company) — Registrant
- March 5, 2024 (date) — Date of earliest event reported
- Needham, MA (location) — Principal Executive Offices
FAQ
What is the primary purpose of this 8-K filing for Candel Therapeutics?
The primary purpose of this 8-K filing is to report on Regulation FD Disclosure and Financial Statements and Exhibits.
What is the exact date of the earliest event reported in this filing?
The date of the earliest event reported is March 5, 2024.
Where are Candel Therapeutics' principal executive offices located?
Candel Therapeutics' principal executive offices are located at 117 Kendrick St., Suite 450, Needham, MA 02494.
What is the Commission File Number for Candel Therapeutics?
The Commission File Number for Candel Therapeutics is 001-40629.
Is this filing related to any specific new product or clinical trial update?
This filing does not specify any new product or clinical trial updates; it is primarily for regulatory and financial reporting.
Filing Stats: 589 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-03-06 08:00:10
Key Financial Figures
- $0.01 — nge on which registered Common Stock, $0.01 par value per share CADL The Nasdaq
Filing Documents
- cadl-20240305.htm (8-K) — 44KB
- cadl-ex99_1.htm (EX-99.1) — 19KB
- img160460863_0.jpg (GRAPHIC) — 26KB
- 0000950170-24-026877.txt ( ) — 221KB
- cadl-20240305.xsd (EX-101.SCH) — 27KB
- cadl-20240305_htm.xml (XML) — 5KB
01 Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On March 5, 2024, Candel Therapeutics, Inc. (the "Company"), announced it will present a poster presentation at the American Association for Cancer Research Annual Meeting taking place April 5-10, 2024, in San Diego, CA. The presentation will describe the second candidate from the enLIGHTEN Discovery Platform, a first-in-class multimodal immunotherapy candidate for induction of tertiary lymphoid structures as a novel therapeutic strategy for solid tumors. A copy of the full press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated by reference herein. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be deemed to be "filed" for the purpose of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section. The information in this Item 7.01 and Exhibit 99.1 of this Current Report on Form 8-K shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, whether made before or after the date of this Current Report on Form 8-K, regardless of any general incorporation language in any such filing.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 99.1 Press Release dated March 5, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. Candel Therapeutics, Inc. Date: March 6, 2024 By: /s/ Paul Peter Tak Paul Peter Tak, M.D., Ph.D., FMedSci President and Chief Executive Officer